Merck suits up for another Opdivo showdown with Keytruda liver cancer approval

Keytruda
Merck's Keytruda nabbed its 14th approval last week. (Merck)

Merck just advanced the Keytruda-Opdivo immuno-oncology rivalry into a brand-new arena.

On Friday, the FDA handed Keytruda a new approval in patients with hepatocellular carcinoma—the most common form of liver cancer in adults—who have already been treated with Bayer’s Nexavar. That’s a group for which regulators cleared Opdivo, Keytruda’s chief nemesis in the PD-1/PD-L1 class, last September.

The agency based its decision on results from a phase 2 trial that showed Keytruda could provoke a response in 17% of patients. Among responders, 89% of patients felt the benefits of therapy for six months or more, and 56% experienced them for a year or more.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

While 17% may sounds like a small percentage, it’s not far behind the 18.2% response rate Opdivo drove en route to its own approval in Nexavar-treated patients. And now, the two will go head-to-head in yet another patient population, adding liver cancer to a list that already includes melanoma, lung cancer and others.

RELATED: Merck's Keytruda makes liver-cancer headway, putting BMS and Bayer on notice

“While we have seen recent therapeutic advancements, there are still limited treatment options for advanced recurrent disease,” Andrew Zhu, M.D., lead investigator for the Merck study, said in a statement, calling Keytruda’s approval “important.”

The thing is, Keytruda and Opdivo—despite being the only two I-O therapies approved for liver cancer patients—aren’t alone on the liver cancer battleground. Bayer, which has long reigned supreme in the disease area thanks to immense success with Nexavar, last year landed a second-line nod for follow-up drug Stivarga. Since then, it’s been working to bill the duo as a regimen, encouraging doctors to keep prescriptions in the family after patients fail on Nexavar.

Merck, though, already has some familiarity with the liver cancer market thanks to an August approval for Lenvima, an Eisai drug in which the New Jersey drugmaker nabbed a 50% stake this March. Lenvima scored a go-ahead in previously untreated patients, setting it up to square off with Nexavar.

Suggested Articles

How long can one infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead showed Saturday.

AbbVie and Roche have fielded their fair share of questions about how well their fixed-duration regimen of Venclexta and Rituxan can keep CLL at bay.

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.